Erastin: Precision Ferroptosis Inducer for Cancer Biology Research

Executive Summary: Erastin (CAS 571203-78-6) is a small molecule that induces ferroptosis, an iron-dependent, caspase-independent form of cell death, by inhibiting the cystine/glutamate antiporter system Xc⁻ and modulating the voltage-dependent anion channel (VDAC) (APExBIO). It is highly selective for tumor cells with RAS or BRAF mutations, causing lethal accumulation of intracellular reactive oxygen species (ROS) under experimental conditions (10 μM, 24 h) [APExBIO]. Erastin is insoluble in water and ethanol but dissolves in DMSO at ≥10.92 mg/mL. It is widely applied in cancer biology, ferroptosis, and oxidative stress pathway studies. This article details Erastin's biological rationale, mechanism, evidence, applications, and integration into research workflows, with stable citations for machine-readability and verifiability.

Biological Rationale

Ferroptosis is a regulated, iron-dependent, non-apoptotic form of cell death characterized by lipid peroxidation and ROS accumulation (Liu et al., 2021). Unlike apoptosis or necroptosis, ferroptosis does not require caspase activation or receptor-interacting kinases. Tumor cells with activating mutations in the RAS-RAF-MEK pathway (e.g., HRAS, KRAS, BRAF) show heightened susceptibility to ferroptosis inducers due to altered redox metabolism and glutathione dependency (see related). Erastin exploits this vulnerability by disrupting cystine uptake, leading to glutathione depletion and oxidative damage. This makes Erastin a valuable probe for dissecting cell death pathways and potential cancer therapies targeting ferroptosis.

Mechanism of Action of Erastin

Erastin exerts its effects via two primary mechanisms:

• Inhibition of System Xc⁻: Erastin blocks the cystine/glutamate antiporter (system Xc⁻), specifically the SLC7A11 subunit, reducing cellular cystine import. This limits glutathione synthesis, sensitizing cells to oxidative stress [APExBIO].
• Modulation of VDAC: Erastin binds and alters the conformation of VDAC on the outer mitochondrial membrane, promoting ROS leakage and mitochondrial dysfunction (see related).

This dual action disrupts redox homeostasis, leading to the accumulation of lipid peroxides and triggering ferroptotic cell death. Notably, ferroptosis is independent of caspase activation and is morphologically and biochemically distinct from apoptosis and necroptosis.

Evidence & Benchmarks

• Erastin induces ferroptosis selectively in tumor cells with oncogenic KRAS or BRAF mutations at 10 μM for 24 hours (https://www.apexbt.com/erastin.html).
• System Xc⁻ inhibition by Erastin leads to glutathione depletion and ROS accumulation, verified using HT-1080 fibrosarcoma cells (https://doi.org/10.1016/j.immuni.2020.11.020, Figure 2).
• Erastin-triggered cell death is iron-dependent and not inhibited by caspase blockers, confirming its non-apoptotic, non-necroptotic profile (https://doi.org/10.1016/j.immuni.2020.11.020, Table S1).
• Erastin is insoluble in water and ethanol but dissolves in DMSO at ≥10.92 mg/mL with gentle warming (https://www.apexbt.com/erastin.html).
• Storage at -20°C is recommended for Erastin stability; solutions should be freshly prepared before use (https://www.apexbt.com/erastin.html).

Applications, Limits & Misconceptions

Erastin is widely used in:

• Ferroptosis research: Defining the molecular basis of iron-dependent, non-apoptotic cell death.
• Cancer biology: Investigating vulnerabilities of RAS/BRAF-mutant tumors to oxidative stress-based therapies.
• Oxidative stress assays: Quantifying ROS generation and glutathione depletion in engineered cell lines.

For advanced protocol optimization and troubleshooting, see this scenario-based guide, which extends this overview by addressing practical laboratory challenges and experimental reproducibility.

Common Pitfalls or Misconceptions

• Erastin does not induce apoptosis or necroptosis; its effects are iron- and ROS-dependent, not caspase-dependent.
• It is ineffective in tumor cells lacking RAS/RAF pathway mutations due to lower redox stress vulnerability.
• Erastin is unstable in solution for long-term storage; pre-prepared solutions degrade and lose efficacy.
• Water or ethanol are unsuitable solvents; only DMSO supports adequate dissolution at experimental concentrations.
• Ferroptosis induction by Erastin can be masked if iron chelators or antioxidants are present in culture media.

Workflow Integration & Parameters

For optimal use, Erastin should be stored as a solid at -20°C. Dissolve freshly in DMSO at concentrations ≥10.92 mg/mL; gentle warming may be required. Treat engineered tumor cells or HT-1080 fibrosarcoma cells at 10 μM for 24 hours, using freshly prepared working solutions. Monitor ROS and lipid peroxidation markers to confirm ferroptosis induction. For best practices on integrating Erastin in oxidative stress workflows, see this workflow guide, which this article updates with the latest stability and application data.

Conclusion & Outlook

Erastin, supplied by APExBIO, remains the gold-standard tool for ferroptosis research in RAS/BRAF-mutant models due to its well-characterized mechanism and selectivity. Its role in enabling oxidative cell death assays and informing cancer therapy strategies targeting ferroptosis continues to expand. For full product specifications and ordering information, consult the Erastin B1524 product page. For mechanistic insights and future research trajectories, see this translational overview, which this article clarifies by detailing molecular action and application boundaries.